Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm

OncoImmunology

Volumn 5, Issue 4, 2016, Pages

  Gulley, James L ^a   Mulders, Peter ^b   Albers, Peter ^c   Banchereau, Jacques ^d   Bolla, Michel ^e   Pantel, Klaus ^f   Powles, Thomas ^g  

^a NATIONAL CANCER INSTITUTE   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d JACKSON LABORATORY   (United States)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Clinical trials; immune responses; immunotherapy; prostate cancer; sipuleucel T

Indexed keywords

ABIRATERONE ACETATE; ACID PHOSPHATASE PROSTATE ISOENZYME; DOCETAXEL; ENZALUTAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; DISEASE COURSE; EOSINOPHIL COUNT; EOSINOPHILIA; HUMAN; IMMUNE RESPONSE; LEUKAPHERESIS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER;

EID: 84962862396     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1107698     Document Type: Article

References (50)

1. Dendreon Corporation. Sipuleucel-T prescribing information. 2014. Available at: http://www.valeant.com/Portals/25/Pdf/PI/Provenge-PI.pdf
2. S.Markowicz, E.G.Engleman. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest 1990; 85:955-61; PMID:2179270; http://dx.doi.org/10.1172/JCI114525
3. E.J.Small, P.Fratesi, D.M.Reese, G.Strang, R.Laus, M.V.Peshwa, F.H.Valone. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894-903; PMID:11099318
4. N.A.Sheikh, D.Petrylak, P.W.Kantoff, C.Dela Rosa, F.P.Stewart, L.Y.Kuan, J.B.Whitmore, J.B.Trager, C.H.Poehlein, M.W.Frohlich et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 2013; 62:137-47; PMID:22865266; http://dx.doi.org/10.1007/s00262-012-1317-2
5. F.J.Hsu, C.Benike, F.Fagnoni, T.M.Liles, D.Czerwinski, B.Taidi, E.G.Engleman, R.Levy. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2:52-8; PMID:8564842; http://dx.doi.org/10.1038/nm0196-52
6. K.W.Lam, C.Y.Li, L.T.Yam, T.Sun, G.Lee, S.Ziesmer. Improved immunohistochemical detection of prostatic acid phosphatase by a monoclonal antibody. Prostate 1989; 15:13-21; PMID:2477829; http://dx.doi.org/10.1002/pros.2990150103
7. E.J.Small, P.F.Schellhammer, C.S.Higano, C.H.Redfern, J.J.Nemunaitis, F.H.Valone, S.S.Verjee, L.A.Jones, R.M.Hershberg. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089-94; PMID:16809734; http://dx.doi.org/10.1200/JCO.2005.04.5252
8. C.S.Higano, P.F.Schellhammer, E.J.Small, P.A.Burch, J.Nemunaitis, L.Yuh, N.Provost, M.W.Frohlich. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115:3670-9; PMID:19536890; http://dx.doi.org/10.1002/cncr.24429
9. P.W.Kantoff, C.S.Higano, N.D.Shore, E.R.Berger, E.J.Small, D.F.Penson, C.H.Redfern, A.C.Ferrari, R.Dreicer, R.B.Sims et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
10. D.P.Petrylak, N.A.Dawson, T.Gardner, L.Klotz, B.D.Curti, R.C.Flanigan, M.N.Fishman, Y.Xu, J.B.Whitmore, M.W.Frohlich. Persistence of immunotherapy survival effects of sipuleucel-T and relationship to postrandomization docetaxel use in phase III studies. J Clin Oncol 2010; 28 (Suppl. 15): Abstract 4551; PMID:20547989
11. T.M.Beer, M.Glode, R.Lance, R.Greengold, H.Haynes, R.Sims, Y.Wang, N.Sheikh, J.Corman. P10-1, an open-label, multicenter study of sipuleucel-T in men with metastatic castrate-resistant prostate cancer (mCRPC) previously treated with sipuleucel-T: analysis of immunological data. Eur J Cancer 2013; 49 (Suppl. 2): Abstract 2909
12. D.G.McNeel, T.A.Gardner, C.S.Higano, P.W.Kantoff, E.J.Small, M.H.Wener, R.B.Sims, T.DeVries, N.A.Sheikh, R.Dreicer. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who received sipuleucel-T. Cancer Immunol Res 2014; 2:988-99; PMID:25189164; http://dx.doi.org/10.1158/2326-6066.CIR-14-0073
13. L.Fong, P.Carroll, V.K.Weinberg, S.Chan, J.Lewis, J.Corman, C.L.Amling, R.A.Stephenson, J.Simko, N.A.Sheikh et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst 2014; 106:pii: dju268; PMID:25255802; http://dx.doi.org/10.1093/jnci/dju268
14. J.L.Gulley, C.G.Drake. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res 2011; 17:3884-91; PMID:21680544; http://dx.doi.org/10.1158/1078-0432.CCR-10-2656
15. J.L.Gulley, R.A.Madan, J.Schlom. Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol 2011; 18:e150-7; PMID:21655153; http://dx.doi.org/10.3747/co.v18i3.783
16. R.A.Madan, T.Schwaab, J.L.Gulley. Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer. J Natl Compr Canc Netw 2012; 10:1505-12; PMID:23221788
17. J.Schlom. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012; 104:599-613; PMID:22395641; http://dx.doi.org/10.1093/jnci/djs033
18. D.S.Chen, I.Mellman. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39:1-10; PMID:23890059; http://dx.doi.org/10.1016/j.immuni.2013.07.012
19. J.L.Gulley. Therapeutic vaccines: the ultimate personalized therapy? Hum Vaccin Immunother. 2013; 9:219-21; PMID:22995839; http://dx.doi.org/10.4161/hv.22106
20. T.M.Beer, G.T.Bernstein, J.M.Corman, L.M.Glode, S.J.Hall, W.L.Poll, P.F.Schellhammer, L.A.Jones, Y.Xu, J.W.Kylstra et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res 2011; 17:4558-67; PMID:21558406; http://dx.doi.org/10.1158/1078-0432.CCR-10-3223
21. E.J.Small, C.S.Higano, P.W.Kantoff, J.B.Whitmore, M.W.Frohlich, D.P.Petrylak. Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T. Prostate Cancer Prostatic Dis 2014; 17:259-64; PMID:24957547; http://dx.doi.org/10.1038/pcan.2014.21
22. Federal Drugs Administration Center for Biologics Evaluation & Research. Report on sipuleucel-T. US Food and Drug Administration 2009. Available at: http://www.fda.gov/downloads/biologicsbloodvaccines/cellulargenetherapyproducts/approvedproducts/ucm214540.pdf
23. K.S.Blum, R.Pabst. Lymphocyte numbers and subsets in the human blood. Do they mirror the situation in all organs? Immunol Lett 2007; 108:45-51; PMID:17129612; http://dx.doi.org/10.1016/j.imlet.2006.10.009
24. J.Sprent, J.H.Cho, O.Boyman, C.D.Surh. T cell homeostasis. Immunol Cell Biol 2008; 86:312-9; PMID:18362947; http://dx.doi.org/10.1038/icb.2008.12
25. E.F.Strasser, R.Zimmermann, V.Weisbach, J.Ringwald, J.Zingsem, R.Eckstein. Mononuclear cell variability and recruitment in non-cytokine-stimulated donors after serial 10-liter leukapheresis procedures. Transfusion 2005; 45:445-52; PMID:15752165; http://dx.doi.org/10.1111/j.1537-2995.2005.04202.x
26. R.C.Flanigan, A.J.Polcari, N.D.Shore, T.H.Price, R.B.Sims, J.C.Maher, J.B.Whitmore, J.M.Corman. An analysis of leukapheresis and central venous catheter use in the randomized, placebo controlled, phase 3 IMPACT trial of Sipuleucel-T for metastatic castrate resistant prostate cancer. J Urol 2013; 189:521-6; PMID:23253957; http://dx.doi.org/10.1016/j.juro.2012.09.029
27. S.J.Hall, L.Klotz, A.J.Pantuck, D.J.George, J.B.Whitmore, M.W.Frohlich, R.B.Sims. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J Urol 2011; 186:877-81; PMID:21788048; http://dx.doi.org/10.1016/j.juro.2011.04.070
28. J.L.Gulley, S.F.Leitman, W.Dahut, J.Schlom. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012; 104:1106; author reply 1109–12; PMID:22825555; http://dx.doi.org/10.1093/jnci/djs280
29. C.M.Kolf, C.D.Bolan, R.A.Wesley, J.N.Browning, S.F.Leitman. Sustained decreases in lymphocyte counts in serial long-term leukapheresis donors. Transfusion 2003; 43:(Suppl.) 28A-9A
30. R.B.Ratts, N.P.Weng. Homeostasis of lymphocytes and monocytes in frequent blood donors. Front Immunol 2012; 3:271; PMID:22936935; http://dx.doi.org/10.3389/fimmu.2012.00271
31. B.C.McLeod, I.Sniecinski, D.Ciavarella, H.Owen, T.H.Price, M.J.Randels, J.W.Smith. Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion 1999; 39:282-8; PMID:10204591; http://dx.doi.org/10.1046/j.1537-2995.1999.39399219285.x
32. R.G.Strauss. Effects on donors of repeated leukocyte losses during plateletpheresis. J Clin Apher 1994; 9:130-4; PMID:7798161; http://dx.doi.org/10.1002/jca.2920090208
33. V.S.Blanchette, J.Dunne, D.Steele, S.McPhail, S.Sklar, D.Algom, M.A.Richter, G.Rock. Immune function in blood donors following short-term lymphocytapheresis. Vox Sang 1985; 49:101-9; PMID:4036082; http://dx.doi.org/10.1111/j.1423-0410.1985.tb00776.x
34. J.L.Gulley, J.Marté, C.R.Heery, R.A.Madan, S.M.Steinberg, S.F.Leitman, K.Y.Tsang, J.Schlom. The impact of leukapheresis on immune cell function in patients with advanced cancer. Cancer Immunol Immunother 2015; 64:1429-35; PMID:26243387; http://dx.doi.org/10.1007/s00262-015-1738-9
35. C.J.Ryan, M.R.Smith, J.S.de Bono, A.Molina, C.J.Logothetis, P.de Souza, K.Fizazi, P.Mainwaparring, J.M.Piulats, S.Ng. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368:138-48; PMID:23228172; http://dx.doi.org/10.1056/NEJMoa1209096
36. J.de Bono, C.Logothetis, A.Molin, K.Fizazi, S.North, L.Chu, K.Chi, R.J.Jones, O.B.Goodman, F.Saad et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995-2005; PMID:21612468; http://dx.doi.org/10.1056/NEJMoa1014618
37. T.Beer, A.Armstrong, D.Rathkopf, Y.Loriot, C.Sternberg, C.Higano, P.Iversen, S.Bhattacharya, J.Carles, S.Chowdhury et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371:424-33; PMID:24881730; http://dx.doi.org/10.1056/NEJMoa1405095
38. H.I.Scher, K.Fizazi, F.Saad, M.E.Taplin, C.N.Sternberg, K.Miller, R.de Wit, P.Mulders, K.N.Chi, N.D.Shore. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187-97; PMID:22894553; http://dx.doi.org/10.1056/NEJMoa1207506
39. J.de Bono, S.Oudard, M.Ozguroglu, S.Hansen, J.-P.Machiels, I.Kocak, G.Gravis, I.Bodrogi, M.J.Mackenzie, L.Shen et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010; 376:1147-54; PMID:20888992; http://dx.doi.org/10.1016/S0140-6736(10)61389-X
40. C.Parker, S.Nilsson, D.Heinrich, S.Helle, J.O'Sullivan, S.Fossa, A.Chodacki, P.Wiechno, J.Logue, M.Seke et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369:213-23; PMID:23863050; http://dx.doi.org/10.1056/NEJMoa1213755
41. J.L.Gulley, P.M.Arlen, R.A.Madan, K.Y.Tsang, M.P.Pazdur, L.Skarupa, J.L.Jones, D.J.Poole, J.P.Higgins, J.W.Hodge. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010; 59:663-74; PMID:19890632; http://dx.doi.org/10.1007/s00262-009-0782-8
42. N.A.Sheikh, E.J.Small, D.I.Quinn, C.S.Higano, D.W.Lin, J.D.Wesley, H.Haynes, F.P.Stewart, C.H.Poehlein, J.B.Trager. Sipuleucel-T product characterization across different disease states of prostate cancer. J Clin Oncol 2012; 30 (Suppl. 5): Abstract 42
43. P.F.Schellhammer, G.Chodak, J.B.Whitmore, R.Sims, M.W.Frohlich, P.W.Kantoff. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 2013; 81:1297-302; PMID:23582482; http://dx.doi.org/10.1016/j.urology.2013.01.061
44. D.R.Berthold, G.R.Pond, F.Soban, R.de Wit, M.Eisenberger, I.F.Tannock. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26:242-5; PMID:18182665; http://dx.doi.org/10.1200/JCO.2007.12.4008
45. E.J.Small, R.S.Lance, T.A.Gardner, L.I.Karsh, L.Fong, C.McCoy, T.DeVries, N.A.Sheikh, D.GuhaThakurta, N.Chang et al. A randomized phase II trial of sipuleucel-T with concurrent vs sequential abiraterone acetate plus prednisone in metastatic castration resistant prostate cancer. Clin Cancer Res 2015; 21:3862-9; PMID:25925891; http://dx.doi.org/10.1158/1078-0432.CCR-15-0079
46. NCCN Clinical Practice Guidelines: Prostate Cancer. V1.2015. National Cancer Network website. www.nccn.org. Accessed September22, 2015.
47. J.S.de Bono, H.I.Scher, R.B.Montgomery, C.Parker, M.C.Miller, H.Tissing, G.V.Doyle, L.W.Terstappen, K.J.Pienta, D.Raghavan. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14:6302-9; PMID:18829513; http://dx.doi.org/10.1158/1078-0432.CCR-08-0872
48. H.I.Scher, M.J.Morris, E.Basch, G.Heller. End points and outcomes in castration-resisant prostate cancer: from clinical trials to clinical practice. J Clin Oncol 2011; 29:3695-704; PMID:21859988; http://dx.doi.org/10.1200/JCO.2011.35.8648
49. Y.Kang, K.Pantel. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 2013; 23:573-81; PMID:23680145; http://dx.doi.org/10.1016/j.ccr.2013.04.017
50. C.Alix-Panabières, K.Pantel. Challenges in circulating tumor cell (CTC) research. Nat Rev Cancer 2014; 14:623-31; PMID:25154812; http://dx.doi.org/10.1038/nrc3820